Ascidian news 87

  • Lambert G
ISSN: 10959203
N/ACitations
Citations of this article
4Readers
Mendeley users who have this article in their library.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral proteins interact with the eukaryotic translation machinery, and inhibitors of translation have potent antiviral effects. We found that the drug plitidepsin (aplidin), which has limited clinical approval, possesses antiviral activity (90% inhibitory concentration = 0.88 nM) that is more potent than remdesivir against SARS-CoV-2 in vitro by a factor of 27.5, with limited toxicity in cell culture. Through the use of a drug-resistant mutant, we show that the antiviral activity of plitidepsin against SARS-CoV-2 is mediated through inhibition of the known target eEF1A (eukaryotic translation elongation factor 1A). We demonstrate the in vivo efficacy of plitidepsin treatment in two mouse models of SARS-CoV-2 infection with a reduction of viral replication in the lungs by two orders of magnitude using prophylactic treatment. Our results indicate that plitidepsin is a promising therapeutic candidate for COVID-19.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Lambert, G. (2021). Ascidian news 87, 87, 1–8.

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 3

75%

Professor / Associate Prof. 1

25%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 3

75%

Social Sciences 1

25%

Save time finding and organizing research with Mendeley

Sign up for free